$11.39 Million in Sales Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter

Wall Street brokerages expect Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to post sales of $11.39 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Pieris Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.70 million and the highest estimate coming in at $30.00 million. Pieris Pharmaceuticals reported sales of $1.34 million during the same quarter last year, which indicates a positive year-over-year growth rate of 750%. The company is scheduled to report its next quarterly earnings report on Wednesday, May 9th.

On average, analysts expect that Pieris Pharmaceuticals will report full-year sales of $11.39 million for the current financial year, with estimates ranging from $15.80 million to $36.30 million. For the next fiscal year, analysts forecast that the company will post sales of $20.35 million per share, with estimates ranging from $12.00 million to $29.20 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Pieris Pharmaceuticals.

How to Become a New Pot Stock Millionaire

A number of brokerages have issued reports on PIRS. Evercore ISI began coverage on Pieris Pharmaceuticals in a research report on Monday, March 19th. They set an “outperform” rating and a $13.00 price target for the company. Jefferies Group began coverage on Pieris Pharmaceuticals in a research report on Monday, March 19th. They set a “buy” rating and a $12.00 price target for the company. BidaskClub lowered Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 17th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Pieris Pharmaceuticals in a research report on Friday, March 9th. Finally, ValuEngine upgraded Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Pieris Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $11.00.

Pieris Pharmaceuticals stock opened at $7.21 on Friday. The company has a market capitalization of $408.22, a price-to-earnings ratio of -17.59 and a beta of 1.50. Pieris Pharmaceuticals has a 52 week low of $2.26 and a 52 week high of $9.75.

In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the business’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $7.35, for a total transaction of $12,565,707.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.05% of the company’s stock.

Several institutional investors have recently made changes to their positions in PIRS. State Street Corp acquired a new stake in shares of Pieris Pharmaceuticals in the second quarter valued at $2,377,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Pieris Pharmaceuticals in the fourth quarter valued at $3,370,000. Northern Trust Corp acquired a new stake in shares of Pieris Pharmaceuticals in the second quarter valued at $1,625,000. Millennium Management LLC lifted its holdings in shares of Pieris Pharmaceuticals by 57.9% in the fourth quarter. Millennium Management LLC now owns 699,771 shares of the biotechnology company’s stock valued at $5,283,000 after buying an additional 256,622 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Pieris Pharmaceuticals by 63.7% in the fourth quarter. Renaissance Technologies LLC now owns 650,100 shares of the biotechnology company’s stock valued at $4,908,000 after buying an additional 253,000 shares during the period. Institutional investors and hedge funds own 47.19% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “$11.39 Million in Sales Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3298121/11-39-million-in-sales-expected-for-pieris-pharmaceuticals-inc-pirs-this-quarter.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Bacanora Lithium Plc  Given Average Recommendation of “Hold” by Analysts
Bacanora Lithium Plc Given Average Recommendation of “Hold” by Analysts
Summit Therapeutics  Given Consensus Rating of “Buy” by Analysts
Summit Therapeutics Given Consensus Rating of “Buy” by Analysts
Analysts Set Iteris, Inc.  PT at $9.50
Analysts Set Iteris, Inc. PT at $9.50
Head-To-Head Contrast: CVR Energy  versus Suncor Energy
Head-To-Head Contrast: CVR Energy versus Suncor Energy
Head-To-Head Contrast: Universal Technical Institute  and The Competition
Head-To-Head Contrast: Universal Technical Institute and The Competition
Reviewing XPO Logistics  & DSV
Reviewing XPO Logistics & DSV


© 2006-2018 Ticker Report. Google+.